

Nu Skin Enterprises Increases Stock Repurchase Authorization

August 2, 2018

PROVO, Utah, Aug. 2, 2018 /PRNewswire/ -- Nu Skin Enterprises, Inc. (NYSE: NUS) today announced that its board of directors has increased its stock repurchase authorization to \$500 million, an approximate \$408 million increase.



"We are confident in our ability to grow the business as we focus on our customer growth strategy," said Mark Lawrence, chief financial officer. "We remain committed to using our financial strength to enhance shareholder value."

About Nu Skin Enterprises, Inc.

Founded more than 30 years ago, Nu Skin Enterprises, Inc. develops and distributes innovative consumer products, offering a comprehensive line of premium-quality beauty and wellness solutions. The company builds upon its scientific expertise in both skin care and nutrition to continually develop innovative product brands that include the Nu Skin® personal care brand, the Pharmanex® nutrition brand, and most recently, the ageLOC® anti-aging brand. The ageLOC brand has generated a loyal following for such products as the ageLOC Youth nutritional supplement, the ageLOC Me® customized skin care system, as well as the ageLOC TR90® weight management and body shaping system. Nu Skin sells its products through a global network of sales leaders in Asia, the Americas, Europe, Africa and the Pacific. As a long-standing member of direct selling associations globally, Nu Skin is committed to the industry's consumer guidelines that protect and support those who sell and purchase its products through the direct selling channel. Nu Skin is also traded on the New York Stock Exchange under the symbol "NUS." More information is available at <u>nuskin.com</u>.

Nu Skin Social Media Channels

fb.com/nuskin twitter.com/nuskin instagram.com/nuskin

C View original content with multimedia: http://www.prnewswire.com/news-releases/nu-skin-enterprises-increases-stock-repurchase-authorization-300691430.html

SOURCE Nu Skin Enterprises, Inc.

Media: media@nuskin.com, (801) 345-6397; Investors: investorrelations@nuskin.com, (801) 345-3577